Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to determine the effectiveness of giving interferon alfa after chemotherapy and peripheral stem cell transplantation to patients who have stage III or stage IV multiple myeloma and who have been treated with high-dose melphalan.

Key facts

Study ID

NCT00003007

Run by

University of Tennessee

Starts

1996-07-01

Expected to finish

2004-01-01

Last updated by the study team

2013-06-26

Who can join

Age: 19 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

• William F. Bowld Hospital — Memphis, Tennessee, United States
• Methodist Healthcare - Hospital of Memphis — Memphis, Tennessee, United States
• Baptist Memorial Hospital — Memphis, Tennessee, United States
• University of Tennessee, Memphis — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.